Patricia A Ganz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3277206/publications.pdf

Version: 2024-02-01

301 papers

25,755 citations

76 h-index 7518 151 g-index

328 all docs 328 docs citations

times ranked

328

24183 citing authors

#	Article	IF	CITATIONS
1	Current practice patterns and gaps in guideline-concordant breast cancer survivorship care. Journal of Cancer Survivorship, 2023, 17, 906-915.	2.9	6
2	Cancerâ€related impairments and functional limitations among longâ€term cancer survivors: Gaps and opportunities for clinical practice. Cancer, 2022, 128, 222-229.	4.1	20
3	Socioeconomic Status and Inflammation in Women with Early-stage Breast Cancer: Mediation by Body Mass Index. Brain, Behavior, and Immunity, 2022, 99, 307-316.	4.1	8
4	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
5	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. Journal of Clinical Oncology, 2022, 40, 1111-1123.	1.6	23
6	Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004. Journal of Clinical Oncology, 2022, 40, 324-334.	1.6	10
7	Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer. Breast Cancer Research and Treatment, 2022, 192, 153-161.	2.5	1
8	Evaluating the Association of Adverse Events and Patient-Reported Symptoms to Endocrine Therapy Tolerability. Journal of Clinical Oncology, 2022, 40, 430-431.	1.6	1
9	NKG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) studya *A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC) Journal of Clinical	1.6	3
10	Abstract P2-11-06: Differential gene expression patterns in healthy breast tissue exhibiting epigenetic age acceleration. Cancer Research, 2022, 82, P2-11-06-P2-11-06.	0.9	0
11	Abstract P3-18-04: Evaluating de -escalation of b reast r adiation (DEBRA) following lumpectomy for breast conservative treatment of stage 1, hr+, HER2-, RS â‱\$8 breast cancer: NRG-BR007 a phase III trial. Cancer Research, 2022, 82, P3-18-04-P3-18-04.	0.9	O
12	A Survivorship Educational Tool for Latino Adolescent and Young Adult Cancer Survivors. Health Promotion Practice, 2022, 23, 861-873.	1.6	1
13	Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. Journal of Clinical Oncology, 2022, 40, 2148-2162.	1.6	18
14	Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care. Nature Reviews Clinical Oncology, 2022, 19, 173-187.	27.6	26
15	The impact of reproductive factors on DNA methylation-based telomere length in healthy breast tissue. Npj Breast Cancer, 2022, 8, 48.	5.2	3
16	Moving the Translational Needle in Breast Cancer Survivorship: Connecting Intervention Research to Clinical Practice. Journal of Clinical Oncology, 2022, 40, 2069-2073.	1.6	4
17	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. Journal of Clinical Oncology, 2022, 40, 3190-3204.	1.6	23
18	Younger women are more susceptible to inflammation: A longitudinal examination of the role of aging in inflammation and depressive symptoms. Journal of Affective Disorders, 2022, 310, 328-336.	4.1	2

#	Article	IF	Citations
19	DNA Methylation, Aging, and Cancer Risk: A Mini-Review. Frontiers in Bioinformatics, 2022, 2, .	2.1	7
20	Healthâ€related quality of life outcomes after neoadjuvantÂchemoradiotherapy for rectal cancer in <scp>NRG</scp> ÂOncology/ <scp>NSABP</scp> Râ€04. Cancer, 2022, 128, 3233-3242.	4.1	3
21	A mixed method study of medical oncologists' perceived barriers and motivators to addressing long-term effects in breast cancer survivors. Breast Cancer Research and Treatment, 2022, 194, 699-707.	2.5	1
22	Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. Journal of the National Cancer Institute, 2021, 113, 1105-1108.	6.3	5
23	Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancer. Cancer, 2021, 127, 1334-1344.	4.1	32
24	Screening for Depression in Younger Breast Cancer Survivors: Outcomes From Use of the 9-item Patient Health Questionnaire. JNCI Cancer Spectrum, 2021, 5, pkab017.	2.9	8
25	The Effects of Lifetime Estrogen Exposure on Breast Epigenetic Age. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1241-1249.	2.5	7
26	NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab. Npj Breast Cancer, 2021, 7, 55.	5.2	4
27	Vulnerability to inflammation-related depressive symptoms: Moderation by stress in women with breast cancer. Brain, Behavior, and Immunity, 2021, 94, 71-78.	4.1	12
28	Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer. New England Journal of Medicine, 2021, 384, 2394-2405.	27.0	764
29	The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	2.4	16
30	Applying the Toxicity Index to Patient-Reported Symptom Data: An Example Using the European Organization for Research and Treatment of Cancer Colorectal Cancer–Specific Quality of Life Questionnaire. Clinical Therapeutics, 2021, 43, 1245-1252.	2.5	1
31	Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education. Journal of Clinical Oncology, 2021, 39, 3473-3484.	1.6	29
32	Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. Journal of Clinical Oncology, 2021, 39, 3800-3812.	1.6	6
33	Association of APOE4 genotype and treatment with cognitive outcomes in breast cancer survivors over time. Npj Breast Cancer, 2021, 7, 112.	5.2	2
34	Cancer-Related Cognitive Impairment in Patients With a History of Breast Cancer. JAMA - Journal of the American Medical Association, 2021, 326, 1736.	7.4	21
35	Visualizing adverse events in clinical trials using correspondence analysis with R-package visae. BMC Medical Research Methodology, 2021, 21, 244.	3.1	2
36	Moderators of inflammation-related depression: a prospective study of breast cancer survivors. Translational Psychiatry, 2021, 11, 615.	4.8	11

#	Article	IF	CITATIONS
37	Endocrine and Metabolic Diseases Among Colorectal Cancer Survivors in a Population-Based Cohort. Journal of the National Cancer Institute, 2020, 112, 78-86.	6.3	10
38	The Hazards of Assessing the Carcinogenicity of Agents. Journal of the National Cancer Institute, 2020, 112, 1-2.	6.3	3
39	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
40	Identifying Cancer-Related Cognitive Impairment Using the FACT-Cog Perceived Cognitive Impairment. JNCI Cancer Spectrum, 2020, 4, pkz099.	2.9	49
41	Prediction of Breast Cancer Treatment–Induced Fatigue by Machine Learning UsingÂGenome-Wide Association Data. JNCI Cancer Spectrum, 2020, 4, pkaa039.	2.9	9
42	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
43	Cognitive Impairment in Patients With Breast Cancer: Understanding the Impact of Chemotherapy and Endocrine Therapy. Journal of Clinical Oncology, 2020, 38, 1871-1874.	1.6	10
44	Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index. Journal of the National Cancer Institute, 2020, 112, 1266-1274.	6.3	24
45	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
46	Childhood maltreatment and monocyte gene expression among women with breast cancer. Brain, Behavior, and Immunity, 2020, 88, 396-402.	4.1	23
47	Incorporating the Risk for Subsequent Primary Cancers Into the Care of Adult Cancer Survivors. JAMA - Journal of the American Medical Association, 2020, 324, 2493.	7.4	9
48	Communicating Risks of Adjuvant Chemotherapy for Breast Cancer: Getting Beyond the Laundry List. Journal of Oncology Practice, 2019, 15, e98-e109.	2.5	7
49	Current state of quality of life and patient-reported outcomes research. European Journal of Cancer, 2019, 121, 55-63.	2.8	83
50	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
51	Goal disturbance in early-stage breast cancer survivors. Journal of Psychosocial Oncology, 2019, 37, 478-493.	1.2	6
52	The spectrum of <i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in Middle Eastern, North African, and South European countries. Human Mutation, 2019, 40, e1-e23.	2.5	34
53	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
54	The inflammation complication: New evidence in cancer-related cognitive impairment. Brain, Behavior, and Immunity, 2019, 81, 6-7.	4.1	3

#	Article	IF	CITATIONS
55	Current US Cancer Statistics: Alarming Trends in Young Adults?. Journal of the National Cancer Institute, 2019, 111, 1241-1242.	6.3	9
56	<i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	2.5	26
57	Can We Find the Positive in Negative Clinical Trials?. Journal of the National Cancer Institute, 2019, 111, 637-638.	6.3	2
58	Health burden in cancer survivors: below the tip of the iceberg. Nature Reviews Clinical Oncology, 2019, 16, 467-468.	27.6	4
59	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
60	Treatment of Nonmetastatic Breast Cancer. JAMA - Journal of the American Medical Association, 2019, 321, 1716.	7.4	26
61	National Outcomes in Hospitalized Patients With Cancer and Comorbid Heart Failure. Journal of Cardiac Failure, 2019, 25, 516-521.	1.7	13
62	Evidence map of ductal carcinoma in situ management options. Menopause, 2019, 26, 1250-1258.	2.0	3
63	Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet, The, 2019, 394, 2155-2164.	13.7	319
64	Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer. Cancer, 2019, 125, 633-641.	4.1	31
65	"Improving to where?― treatment-related health risks and perceptions of the future among adolescents and young adults after hematopoietic cell transplantation. Supportive Care in Cancer, 2019, 27, 623-630.	2.2	1
66	The cognitive effects of endocrine therapy in survivors of breast cancer: A prospective longitudinal study up to 6 years after treatment. Cancer, 2019, 125, 681-689.	4.1	37
67	Cognitive performance in survivors of breast cancer and markers of biological aging. Cancer, 2019, 125, 298-306.	4.1	39
68	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> / <i></i> / <i></i> Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
69	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant	1.6	38
70	Chemotherapy (MC).: Journal of Clinical Oncology, 2013, 37, TP3600-TP3600. Coming of Age With Cancer: Physical, Social, and Financial Barriers to Independence Among Emerging Adult Survivors. Oncology Nursing Forum, 2018, 45, 148-158.	1.2	12
71	Changes in Body Mass Index and Physical Activity Predict Changes in Vitality During a Weight Loss Trial in Breast Cancer Survivors. Annals of Behavioral Medicine, 2018, 52, 999-1009.	2.9	9
72	Disparities in the survivorship experience among Latina survivors of breast cancer. Cancer, 2018, 124, 2373-2380.	4.1	22

#	Article	IF	CITATIONS
73	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1 </i> i>BRCA2 i>mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
74	Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study. Gynecologic Oncology, 2018, 148, 499-506.	1.4	33
75	Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review. Journal of the National Cancer Institute, 2018, 110, .	6.3	54
76	Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. Journal of the National Cancer Institute, 2018, 110, .	6.3	85
77	Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. Journal of Clinical Oncology, 2018, 36, 492-511.	1.6	208
78	Potential Mechanisms of Age Acceleration Caused by Estrogen Deprivation: Do Endocrine Therapies Carry the Same Risks?. JNCI Cancer Spectrum, 2018, 2, pky035.	2.9	11
79	Prometastatic Molecular Profiles in Breast Tumors From Socially Isolated Women. JNCI Cancer Spectrum, 2018, 2, pky029.	2.9	35
80	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
81	Risk Factors for Cardiovascular Disease Among Thyroid Cancer Survivors: Findings From the Utah Cancer Survivors Study. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2468-2477.	3.6	28
82	Long-term Cardiovascular Outcomes Among Endometrial Cancer Survivors in a Large, Population-Based Cohort Study. Journal of the National Cancer Institute, 2018, 110, 1342-1351.	6.3	17
83	Cognitive function following breast cancer treatment and associations with concurrent symptoms. Npj Breast Cancer, 2018, 4, 25.	5.2	25
84	Reproductive and gynecological complication risks among thyroid cancer survivors. Journal of Cancer Survivorship, 2018, 12, 702-711.	2.9	12
85	Fatigue after breast cancer treatment: Biobehavioral predictors of fatigue trajectories Health Psychology, 2018, 37, 1025-1034.	1.6	87
86	Posttraumatic growth in breast cancer survivors: does age matter?. Psycho-Oncology, 2017, 26, 800-807.	2.3	47
87	Doctor, Now That My Chemotherapy Treatment Is Over, When Will My "Chemofog―Lift?. Journal of Clinical Oncology, 2017, 35, 482-484.	1.6	13
88	Young adult cancer survivors and work: a systematic review. Journal of Cancer Survivorship, 2017, 11, 765-781.	2.9	99
89	Inflammation and attentional bias in breast cancer survivors. Brain, Behavior, and Immunity, 2017, 66, 85-88.	4.1	10
90	DNA methylation age is elevated in breast tissue of healthy women. Breast Cancer Research and Treatment, 2017, 164, 209-219.	2.5	52

#	Article	IF	Citations
91	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
92	Improvements in emotion regulation following mindfulness meditation: Effects on depressive symptoms and perceived stress in younger breast cancer survivors Journal of Consulting and Clinical Psychology, 2017, 85, 397-402.	2.0	64
93	Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors. Supportive Care in Cancer, 2017, 25, 739-748.	2.2	5
94	A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer. JAMA Oncology, 2017, 3, 677.	7.1	167
95	Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncology, The, 2017, 18, e653-e706.	10.7	153
96	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
97	Childhood maltreatment, psychological resources, and depressive symptoms in women with breast cancer. Child Abuse and Neglect, 2017, 72, 360-369.	2.6	21
98	Evaluating cognitive complaints in breast cancer survivors with the FACT-Cog and quantitative electroencephalography. Breast Cancer Research and Treatment, 2017, 166, 157-166.	2.5	11
99	Effects of mindfulness training on emotional and physiologic recovery from induced negative affect. Psychoneuroendocrinology, 2017, 86, 78-86.	2.7	40
100	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
101	Quality of life and symptoms in long-term survivors of colorectal cancer: results from NSABP protocol LTS-01. Journal of Cancer Survivorship, 2017, 11, 111-118.	2.9	30
102	Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. Journal of Cancer Survivorship, 2017, 11, 32-40.	2.9	3
103	Biomarkers of aging associated with past treatments in breast cancer survivors. Npj Breast Cancer, 2017, 3, 50.	5.2	36
104	Editorial: Changing of the Guard at the Journal of the National Cancer Institute. Journal of the National Cancer Institute, 2017, 109, .	6.3	0
105	"From Snail Mode to Rocket Ship Mode― Adolescents and Young Adults' Experiences of Returning to Work and School After Hematopoietic Cell Transplantation. Journal of Adolescent and Young Adult Oncology, 2017, 6, 551-559.	1.3	31
106	Aging-Related Disease Risks among Young Thyroid Cancer Survivors. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1695-1704.	2.5	30
107	Randomized Controlled Trial of Survivorship Care Plans Among Low-Income, Predominantly Latina Breast Cancer Survivors. Journal of Clinical Oncology, 2017, 35, 1814-1821.	1.6	62
108	Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 674-683.	3.8	18

#	Article	IF	Citations
109	Reply to P. Tralongo et al. Journal of Clinical Oncology, 2017, 35, 3517-3517.	1.6	1
110	Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial. Journal of Clinical Oncology, 2017, 35, 2656-2665.	1.6	139
111	Cong-Term Follow-up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth	1.6	55
112	Going Beyond Being Lost in Transition: A Decade of Progress in Cancer Survivorship. Journal of Clinical Oncology, 2017, 35, 1978-1981.	1.6	118
113	Cortisol Awakening Response as a Prospective Risk Factor for Depressive Symptoms in Women After Treatment for Breast Cancer. Psychosomatic Medicine, 2017, 79, 763-769.	2.0	18
114	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypNO after neoadjuvant chemotherapy (NC)	1.6	9
115	Journal of Clinical Oncology, 2017, 35, TPS589-TPS589. Challenges and Opportunities in Delivering High-Quality Cancer Care: A 2016 Update. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e294-e300.	3.8	4
116	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
117	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. JAMA Oncology, 2016, 2, 1434.	7.1	189
118	Positive Affect and Inflammatory Activity in Breast Cancer Survivors: Examining the Role of Affective Arousal. Psychosomatic Medicine, 2016, 78, 532-541.	2.0	30
119	Improving the Quality and Value of Cancer Care: A Work in Progress—The 2016 Joseph V. Simone Award and Lecture. Journal of Oncology Practice, 2016, 12, 876-879.	2.5	7
120	"Winging It― How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment. Journal of Oncology Practice, 2016, 12, e991-e1000.	2.5	16
121	Impact of a behavioral weight loss intervention on comorbidities in overweight and obese breast cancer survivors. Supportive Care in Cancer, 2016, 24, 3285-3293.	2.2	11
122	Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. Journal of Affective Disorders, 2016, 197, 43-50.	4.1	34
123	Subjective or Objective Measures of Cognitive Functioning—What's More Important?. JAMA Oncology, 2016, 2, 1263.	7.1	60
124	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. Ca-A Cancer Journal for Clinicians, 2016, 66, 43-73.	329.8	497
125	Measuring cognitive complaints in breast cancer survivors: psychometric properties of the patient's assessment of own functioning inventory. Supportive Care in Cancer, 2016, 24, 4939-4949.	2.2	12
126	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	5.0	42

#	Article	IF	Citations
127	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
128	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
129	Understanding the impact of breast cancer adjuvant endocrine therapy on cognitive function: a work in progress. British Journal of Cancer, 2016, 114, 953-955.	6.4	4
130	Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial. Psycho-Oncology, 2016, 25, 142-149.	2.3	12
131	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. Journal of Clinical Oncology, 2016, 34, 2925-2934.	1.6	538
132	Quality of Posttreatment Care Among Breast Cancer Survivors in the University of California Athena Breast Health Network (Athena). Clinical Breast Cancer, 2016, 16, 356-363.	2.4	3
133	Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study. Journal of Clinical Oncology, 2016, 34, 816-824.	1.6	83
134	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. Journal of Clinical Oncology, 2016, 34, 611-635.	1.6	651
135	Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet, The, 2016, 387, 849-856.	13.7	148
136	Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet, The, 2016, 387, 857-865.	13.7	67
137	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2016, 34, 987-1011.	1.6	141
138	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
139	Painful Hands and Feet After Cancer Treatment: Inflammation Affecting the Mind-Body Connection. Journal of Clinical Oncology, 2016, 34, 649-652.	1.6	7
140	Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1. Journal of the National Cancer Institute, 2016, 108, djv365.	6.3	28
141	Development and pilot testing of a psychosocial intervention program for young breast cancer survivors. Patient Education and Counseling, 2016, 99, 414-420.	2.2	10
142	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who after neoadjuvant chemotherapy (NC)	1.6	0
143	Journal of Clinical Oncology, 2016, 34, TPS1097-TPS1097. Disparities in breast cancer care and research: report from a Breast Cancer Research Foundation sponsored workshop, 9–10 October 2014. Npj Breast Cancer, 2015, 1, 15013.	5.2	6
144	Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors. Breast Cancer Research and Treatment, 2015, 154, 329-337.	2.5	38

#	Article	IF	Citations
145	Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of firstâ€degree relatives. Cancer, 2015, 121, 2951-2959.	4.1	17
146	How much do cancerâ€related symptoms contribute to healthâ€related quality of life in lung and colorectal cancer patients? A report from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium. Cancer, 2015, 121, 2831-2839.	4.1	25
147	Identifying and Addressing the Needs of Adolescents and Young Adults With Cancer: Summary of an Institute of Medicine Workshop. Oncologist, 2015, 20, 186-195.	3.7	224
148	Outcomes and Satisfaction After Delivery of a Breast Cancer Survivorship Care Plan: Results of a Multicenter Trial. Journal of Oncology Practice, 2015, 11, e222-e229.	2.5	51
149	Improving breast cancer survivors' knowledge using a patient-centered intervention. Surgery, 2015, 158, 669-675.	1.9	12
150	Mindfulness meditation for younger breast cancer survivors: A randomized controlled trial. Cancer, 2015, 121, 1231-1240.	4.1	267
151	Depression and vasomotor symptoms in young breast cancer survivors: the mediating role of sleep disturbance. Archives of Women's Mental Health, 2015, 18, 565-568.	2.6	27
152	Motivations associated with physical activity in young breast cancer survivors. Psychology, Health and Medicine, 2015, 20, 393-399.	2.4	6
153	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. Journal of Clinical Oncology, 2015, 33, 2563-2577.	1.6	783
154	Delivering Patient-Centered Care in the Setting of Advanced Cancer. JAMA Oncology, 2015, 1, 430.	7.1	6
155	Breast Cancer Survivorship: Where Are We Today?. Advances in Experimental Medicine and Biology, 2015, 862, 1-8.	1.6	82
156	Quality of life over 5 years after a breast cancer diagnosis among lowâ€income women: Effects of race/ethnicity and patientâ€physician communication. Cancer, 2015, 121, 916-926.	4.1	54
157	Life after diagnosis and treatment of cancer in adulthood: Contributions from psychosocial oncology research American Psychologist, 2015, 70, 159-174.	4.2	144
158	Living with Metastatic Breast Cancer. Advances in Experimental Medicine and Biology, 2015, 862, 243-254.	1.6	11
159	Quality of Care, Including Survivorship Care Plans. Advances in Experimental Medicine and Biology, 2015, 862, 255-269.	1.6	6
160	Special Issues in Younger Women with Breast Cancer. Advances in Experimental Medicine and Biology, 2015, 862, 9-21.	1.6	11
161	Post-traumatic stress symptoms in cancer survivors: relationship to the impact of cancer scale and other associated risk factors. Psycho-Oncology, 2015, 24, 643-652.	2.3	45
162	Are primary care providers prepared to care for survivors of breast cancer in the safety net?. Cancer, 2015, 121, 1249-1256.	4.1	40

#	Article	IF	CITATIONS
163	Association of Type and Location of <i>BRCA1</i> BRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
164	Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors. Journal of Clinical Oncology, 2015, 33, 3169-3176.	1.6	173
165	Cost-effectiveness of UniversalBRCA1/2Screening. JAMA Oncology, 2015, 1, 1217.	7.1	33
166	Symptoms: Fatigue and Cognitive Dysfunction. Advances in Experimental Medicine and Biology, 2015, 862, 53-75.	1.6	31
167	Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer Journal of Clinical Oncology, 2015, 33, 1500-1500.	1.6	5
168	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypNO after neoadjuvant chemotherapy (NC) Journal of Clinical Oncology,	1.6	1
169	2015, 33, TPS11112-TPS11112. Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy Journal of Clinical Oncology, 2015, 33, LBA500-LBA500.	1.6	12
170	Implementing the Survivorship Care Plan. , 2015, , 644-650.		0
171	Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: A behavioral weight loss intervention in overweight or obese breast cancer survivors Journal of Clinical Oncology, 2015, 33, 9506-9506.	1.6	2
172	Fatigue in long-term non-Hodgkin lymphoma survivors Journal of Clinical Oncology, 2015, 33, e20628-e20628.	1.6	0
173	Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy Journal of Clinical Oncology, 2015, 33, LBA500-LBA500.	1.6	0
174	Cognitive Function After the Initiation of Adjuvant Endocrine Therapy in Early-Stage Breast Cancer: An Observational Cohort Study. Journal of Clinical Oncology, 2014, 32, 3559-3567.	1.6	78
175	Improving the quality of cancer care in America through health information technology. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 772-775.	4.4	15
176	Tai Chi, Cellular Inflammation, and Transcriptome Dynamics in Breast Cancer Survivors With Insomnia: A Randomized Controlled Trial. Journal of the National Cancer Institute Monographs, 2014, 2014, 295-301.	2.1	113
177	Cancer Survivors: A Look Backward and Forward. Journal of Oncology Practice, 2014, 10, 289-293.	2.5	7
178	Childhood Adversity and Inflammation in Breast Cancer Survivors. Psychosomatic Medicine, 2014, 76, 208-214.	2.0	39
179	Effect of Depression on Diagnosis, Treatment, and Mortality of Men With Clinically Localized Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 2471-2478.	1.6	115
180	Low heart rate variability and cancer-related fatigue in breast cancer survivors. Psychoneuroendocrinology, 2014, 45, 58-66.	2.7	92

#	Article	IF	CITATIONS
181	Provision and Discussion of Survivorship Care Plans Among Cancer Survivors: Results of a Nationally Representative Survey of Oncologists and Primary Care Physicians. Journal of Clinical Oncology, 2014, 32, 1578-1585.	1.6	163
182	Yoga reduces inflammatory signaling in fatigued breast cancer survivors: A randomized controlled trial. Psychoneuroendocrinology, 2014, 43, 20-29.	2.7	211
183	Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation. Journal of Clinical Oncology, 2014, 32, 1840-1850.	1.6	486
184	Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. European Urology, 2014, 66, 666-672.	1.9	97
185	Cancer-related intrusive thoughts predict behavioral symptoms following breast cancer treatment Health Psychology, 2014, 33, 155-163.	1.6	66
186	Reply to I.E. Haines. Journal of Clinical Oncology, 2014, 32, 1978-1978.	1.6	1
187	Health Services Utilisation in Breast Cancer Survivors in Taiwan. Scientific Reports, 2014, 4, 7466.	3.3	3
188	Patient-reported outcomes and behavioral risk factors as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention P-1 trial Journal of Clinical Oncology, 2014, 32, 1512-1512.	1.6	1
189	Barriers to physical activity and healthy eating in young breast cancer survivors: modifiable risk factors and associations with body mass index. Breast Cancer Research and Treatment, 2013, 142, 423-433.	2.5	49
190	Sleep disturbance, inflammation and depression risk in cancer survivors. Brain, Behavior, and Immunity, 2013, 30, S58-S67.	4.1	126
191	Does tumor necrosis factor-alpha (TNF- \hat{l} ±) play a role in post-chemotherapy cerebral dysfunction?. Brain, Behavior, and Immunity, 2013, 30, S99-S108.	4.1	143
192	Decline in physical functioning in first 2Âyears after breast cancer diagnosis predicts 10-year survival in older women. Journal of Cancer Survivorship, 2013, 7, 20-31.	2.9	74
193	Identifying Tools and Strategies to Provide Quality Oncology Care. Journal of Oncology Practice, 2013, 9, 125-127.	2.5	1
194	Cognitive Complaints After Breast Cancer Treatments: Examining the Relationship With Neuropsychological Test Performance. Journal of the National Cancer Institute, 2013, 105, 791-801.	6.3	173
195	Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop. Journal of Oncology Practice, 2013, 9, 54s-59s.	2.5	7
196	Charting a New Course for the Delivery of High-Quality Cancer Care. Journal of Clinical Oncology, 2013, 31, 4485-4487.	1.6	29
197	Quality of Life, Fertility Concerns, and Behavioral Health Outcomes in Younger Breast Cancer Survivors: A Systematic Review. Journal of the National Cancer Institute, 2012, 104, 386-405.	6.3	659
198	Host Factors, Behaviors, and Clinical Trials: Opportunities and Challenges. Journal of Clinical Oncology, 2012, 30, 2817-2819.	1.6	10

#	Article	IF	CITATIONS
199	"Doctor, Will the Treatment You Are Recommending Cause Chemobrain?― Journal of Clinical Oncology, 2012, 30, 229-231.	1.6	35
200	<i>Journal of Clinical Oncology</i> Update on Progress in Cancer Survivorship Care and Research. Journal of Clinical Oncology, 2012, 30, 3655-3656.	1.6	31
201	New Fibrate Use and Acute Renal Outcomes in Elderly Adults. Annals of Internal Medicine, 2012, 156, 560.	3.9	192
202	The Role of Rehabilitation in the Older Patient with Cancer. , 2012, , 207-212.		0
203	NSABP B-47: A phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel) IJ ETQq. node-negative, HER2-low invasive breast cancer Journal of Clinical Oncology, 2012, 30,	1 1 0./84. 1.6	314 rgBT /O
204	Fatigue and gene expression in human leukocytes: Increased NF-κB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain, Behavior, and Immunity, 2011, 25, 147-150.	4.1	145
205	Quality of Life Assessment in Breast Cancer: When Does it Add Prognostic Value for Survival?. Breast Journal, 2011, 17, 569-570.	1.0	4
206	Relevant Endpoints for Advanced Breast Cancer Patients. Breast, 2011, 20, S18.	2.2	0
207	Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Research and Treatment, 2011, 129, 549-556.	2.5	124
208	Q&A: The 'three Ps' of cancer survivorship care. BMC Medicine, 2011, 9, 14.	5.5	25
209	Expanding Our Therapeutic Options: Beta Blockers for Breast Cancer?. Journal of Clinical Oncology, 2011, 29, 2612-2616.	1.6	26
210	Impact of Survivorship-Based Research on Defining Clinical Care Guidelines. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2085-2092.	2.5	30
211	Physical and Psychosocial Recovery in the Year After Primary Treatment of Breast Cancer. Journal of Clinical Oncology, 2011, 29, 1101-1109.	1.6	207
212	Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial. Journal of Clinical Oncology, 2011, 29, 1110-1116.	1.6	108
213	Inflammation and Behavioral Symptoms After Breast Cancer Treatment: Do Fatigue, Depression, and Sleep Disturbance Share a Common Underlying Mechanism?. Journal of Clinical Oncology, 2011, 29, 3517-3522.	1.6	414
214	Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prevention Research, 2011, 4, 1393-1400.	1.5	57
215	Optimizing Health: Oncology Care. , 2011, , 205-221.		0
216	NIH State-of-the-Science Conference Statement: Role of active surveillance in the management of men with localized prostate cancer. NIH Consensus and State-of-the-science Statements, 2011, 28, 1-27.	7.0	21

#	Article	IF	Citations
217	Estimating the Human Costs of Cancer Survivorship in Children. Annals of Internal Medicine, 2010, 152, 465.	3.9	2
218	Improving Breast Cancer Quality of Care with the Use of Patient Navigators. American Surgeon, 2010, 76, 1043-1046.	0.8	22
219	Harnessing personalised medicine to prevent late effects. Lancet Oncology, The, 2010, 11, 7-9.	10.7	10
220	Implementing the Survivorship Care Plan: A Strategy for Improving the Quality of Care for Cancer Survivors., 2010,, 557-561.		0
221	Inflammatory Biomarkers and Fatigue during Radiation Therapy for Breast and Prostate Cancer. Clinical Cancer Research, 2009, 15, 5534-5540.	7.0	264
222	Quality of Care and Cancer Survivorship: The Challenge of Implementing the Institute of Medicine Recommendations. Journal of Oncology Practice, 2009, 5, 101-105.	2.5	51
223	Pediatric Cancer Survivorship: The Childhood Cancer Survivor Study—Editor's Foreword. Journal of Clinical Oncology, 2009, 27, 2307-2307.	1.6	9
224	Neuropsychological studies in breast cancer: in search of chemobrain. Breast Cancer Research and Treatment, 2009, 116, 125-127.	2.5	25
225	Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention. Breast Cancer Research and Treatment, 2009, 118, 99-111.	2.5	93
226	Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. Journal of Cancer Survivorship, 2009, 3, 137-147.	2.9	44
227	Survivorship: Adult Cancer Survivors. Primary Care - Clinics in Office Practice, 2009, 36, 721-741.	1.6	191
228	Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Research and Treatment, 2008, 109, 515-526.	2.5	64
229	Breast Cancer Rehabilitation and Survivorship: Cost, Quality, and Lessons Learned. Seminars in Breast Disease, 2008, 11, 148-153.	0.0	0
230	Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897. Journal of Clinical Oncology, 2008, 26, 1223-1230.	1.6	78
231	Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer. Menopause, 2008, 15, 797-803.	2.0	12
232	Psychological and social aspects of breast cancer. Oncology, 2008, 22, 642-6, 650; discussion 650, 653.	0.5	58
233	Compliance With Patient-Reported Outcomes in Multicenter Clinical Trials: Methodologic and Practical Approaches. Journal of Clinical Oncology, 2007, 25, 5113-5120.	1.6	27
234	Older Breast Cancer Survivors: Factors Associated With Change in Emotional Well-Being. Journal of Clinical Oncology, 2007, 25, 1334-1340.	1.6	46

#	Article	IF	CITATIONS
235	Use of Patient-Reported Outcomes in Phase III Cancer Treatment Trials: Lessons Learned and Future Directions. Journal of Clinical Oncology, 2007, 25, 5063-5069.	1.6	42
236	Economic Evaluation in the Journal of Clinical Oncology: Past, Present, and Future. Journal of Clinical Oncology, 2007, 25, 614-616.	1.6	16
237	Health-Related Quality of Life Measurement in Symptom Management Trials. Journal of the National Cancer Institute Monographs, 2007, 2007, 47-52.	2.1	8
238	Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10Âyears after chemotherapy. Breast Cancer Research and Treatment, 2007, 103, 303-311.	2.5	349
239	Cancer Survivors: A Physician's Perspective. , 2007, , 1-7.		2
240	The Survivorship Care Plan: What, Why, How, and for Whom., 2007,, 287-293.		3
241	Inflammatory Biomarkers for Persistent Fatigue in Breast Cancer Survivors. Clinical Cancer Research, 2006, 12, 2759-2766.	7.0	351
242	Adjuvant Therapy for Breast Cancer: No Pain, No Gain?. Breast Diseases, 2006, 16, 320-322.	0.0	2
243	Fatigue in longâ€term breast carcinoma survivors. Cancer, 2006, 106, 751-758.	4.1	586
244	Monitoring the Physical Health of Cancer Survivors: A Survivorship-Focused Medical History. Journal of Clinical Oncology, 2006, 24, 5105-5111.	1.6	113
245	Suicide After Breast Cancer: an International Population-Based Study of 723 810 Women. Journal of the National Cancer Institute, 2006, 98, 1416-1419.	6.3	106
246	Altered Cortisol Response to Psychologic Stress in Breast Cancer Survivors With Persistent Fatigue. Psychosomatic Medicine, 2005, 67, 277-280.	2.0	195
247	Breast cancer risk: is postmenopausal hormone therapy ever safe?. Menopause, 2005, 12, 653-655.	2.0	4
248	Promoting adjustment after treatment for cancer. Cancer, 2005, 104, 2608-2613.	4.1	185
249	The BCPT Symptom Scales: A Measure of Physical Symptoms for Women Diagnosed With or at Risk for Breast Cancer. Journal of the National Cancer Institute, 2005, 97, 448-456.	6.3	154
250	Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. American Journal of Medicine, 2005, 118, 136-141.	1.5	71
251	Breast cancer, menopause, and long-term survivorship: Critical issues for the 21st century. American Journal of Medicine, 2005, 118, 1410.	1.5	2
252	Cognitive Impairment Associated With Chemotherapy for Cancer: Report of a Workshop. Journal of Clinical Oncology, 2004, 22, 2233-2239.	1.6	400

#	Article	IF	Citations
253	Neurocognitive Performance in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy and Tamoxifen. Journal of Clinical and Experimental Neuropsychology, 2004, 26, 955-969.	1.3	338
254	Health-Related Quality of Life in Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer Patients Undergoing AC Versus CMF Chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Research and Treatment, 2004, 86, 153-164.	2.5	61
255	Quality of Life of Breast Cancer Survivors After a Recurrence: A Follow-Up Study. Breast Cancer Research and Treatment, 2004, 87, 45-57.	2.5	77
256	Quality of Life at the End of Primary Treatment of Breast Cancer: First Results From the Moving Beyond Cancer Randomized Trial. Journal of the National Cancer Institute, 2004, 96, 376-387.	6.3	429
257	Breast Cancer in Younger Women: Reproductive and Late Health Effects of Treatment. Journal of Clinical Oncology, 2003, 21, 4184-4193.	1.6	437
258	Breast Cancer in Older Women: Quality of Life and Psychosocial Adjustment in the 15 Months After Diagnosis. Journal of Clinical Oncology, 2003, 21, 4027-4033.	1.6	227
259	Improving colorectal cancer screening rates in a managed care health plan: recruitment of provider organizations for a randomized effectiveness trial. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 824-9.	2.5	8
260	Quality of Life in Long-Term, Disease-Free Survivors of Breast Cancer: a Follow-up Study. Journal of the National Cancer Institute, 2002, 94, 39-49.	6.3	850
261	What Outcomes Matter to Patients. Medical Care, 2002, 40, III-11-III-19.	2.4	34
262	Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors. Psychosomatic Medicine, 2002, 64, 604-611.	2.0	467
263	The price of anticancer intervention. Lancet Oncology, The, 2002, 3, 575-579.	10.7	4
264	What outcomes matter to patients: a physician-researcher point of view. Medical Care, 2002, 40, III11-9.	2.4	14
265	Late effects of cancer and its treatment. Seminars in Oncology Nursing, 2001, 17, 241-248.	1.5	131
266	Prostate Cancer: The Price of Early Detection. Journal of Clinical Oncology, 2001, 19, 1587-1588.	1.6	10
267	Menopause and Breast Cancer: Addressing the Secondary Health Effects of Adjuvant Chemotherapy. Journal of Clinical Oncology, 2001, 19, 3303-3305.	1.6	13
268	Psychologic Distress and Natural Menopause: A Multiethnic Community Study. American Journal of Public Health, 2001, 91, 1435-1442.	2.7	221
269	The role of hormones in breast carcinogenesis: Issues of relevance to female childhood cancer survivors. Medical and Pediatric Oncology, 2001, 36, 514-518.	1.0	5
270	Menopause and breast cancer: Symptoms, late effects, and their management. Seminars in Oncology, 2001, 28, 274-283.	2.2	24

#	Article	IF	Citations
271	Fatigue in Breast Cancer Survivors: Occurrence, Correlates, and Impact on Quality of Life. Journal of Clinical Oncology, 2000, 18, 743-743.	1.6	960
272	Organizational systems used by California capitated medical groups and independent practice associations to increase cancer screening. Cancer, 2000, 88, 2824-2831.	4.1	15
273	Quality of Life Across the Continuum of Breast Cancer Care. Breast Journal, 2000, 6, 324-330.	1.0	49
274	Managing Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial. Journal of the National Cancer Institute, 2000, 92, 1054-1064.	6.3	281
275	Role of Breast Reconstructive Surgery in Physical and Emotional Outcomes Among Breast Cancer Survivors. Journal of the National Cancer Institute, 2000, 92, 1422-1429.	6.3	481
276	Behavioral Science Research in the Cooperative Group Setting: the Southwest Oncology Group Experience. Journal of the National Cancer Institute, 2000, 92, 1381-1387.	6.3	8
277	Predictors of Sexual Health in Women After a Breast Cancer Diagnosis. Journal of Clinical Oncology, 1999, 17, 2371-2371.	1.6	324
278	Quality of life of African-American and white long term breast carcinoma survivors., 1999, 85, 418-426.		177
279	Psychosocial Concerns and Quality of Life in Breast Cancer Survivors. Cancer Investigation, 1999, 17, 342-348.	1.3	56
280	The Status of Cancer Rehabilitation in the Late 1990s. Mayo Clinic Proceedings, 1999, 74, 939-940.	3.0	11
281	Sexuality following breast cancer. Journal of Sex and Marital Therapy, 1999, 25, 237-250.	1.5	144
282	Quality of Life and Cancer Rehabilitation. Rehabilitation Oncology, 1999, 17, 9-11.	0.5	1
283	Quality of Life Research: Clinical Applications. , 1998, 97, 1-12.		4
284	Understanding the Breast Cancer Experience of African-American Women. Journal of Psychosocial Oncology, 1997, 15, 19-35.	1.2	89
285	Acceptability of Mobile Mammography Among Communityâ€Dwelling Older Women. Journal of the American Geriatrics Society, 1997, 45, 1365-1370.	2.6	15
286	Interaction between the physician and the older patient. , 1997, 80, 1323-1325.		19
287	Assessing the quality of life of HIV infected persons: Clinical and descriptive information from studies with the hopes. Psychology and Health, 1994, 9, 93-110.	2.2	23
288	Quality of Life Measures in Cancer Chemotherapy. Pharmacoeconomics, 1994, 5, 376-388.	3.3	17

#	Article	IF	CITATIONS
289	Psychosocial issues in lung cancer patients. Cancer Treatment and Research, 1994, 72, 363-390.	0.5	13
290	Quality-of-Life Assessment in Cancer Clinical Trials: A Status Report. Journal of the National Cancer Institute, 1992, 84, 994-995.	6.3	23
291	Breast conservationversus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery?. Cancer, 1992, 69, 1729-1738.	4.1	303
292	Psychosocial Issues in Lung Cancer Patients (part 2). Chest, 1991, 99, 480-485.	0.8	29
293	Survival in Acute Leukemia in Elderly Patients. Journal of the American Geriatrics Society, 1991, 39, 102-102.	2.6	2
294	Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer, 1991, 67, 3131-3135.	4.1	331
295	CAncer rehabilitation evaluation system–short form (CARES-SF). A cancer specific rehabilitation and quality of life instrument. Cancer, 1991, 68, 1406-1413.	4.1	341
296	Current issues in cancer rehabilitation. Cancer, 1990, 65, 742-751.	4.1	54
297	Methods of Assessing the Effect of Drug Therapy on Quality of Life. Drug Safety, 1990, 5, 233-242.	3.2	24
298	Patient Education as a Moderator of Psychological Distress. Journal of Psychosocial Oncology, 1988, 6, 181-197.	1.2	18
299	Professional Attitudes Toward Hospice Care. Journal of Pain and Palliative Care Pharmacotherapy, 1985, 1, 1-15.	0.2	1
300	Professional Attitudes Toward Hospice Care. Journal of Pain and Palliative Care Pharmacotherapy, 1985, 1, 1-15.	0.2	4
301	Responses of patients with neoplastic diseases to influenza virus vaccine. Cancer, 1978, 42, 2244-2247.	4.1	55